A dual mechanism of action of AT-527 against SARS-CoV-2 polymerase

The guanosine analog AT-527 represents a promising candidate against Severe Acute Respiratory Syndrome coronavirus type 2 (SARS-CoV-2). AT-527 recently entered phase III clinical trials for the treatment of COVID-19. Once in cells, AT-527 is converted into its triphosphate form, AT-9010, that presum...

Descripción completa

Detalles Bibliográficos
Autores principales: Shannon, Ashleigh, Fattorini, Véronique, Sama, Bhawna, Selisko, Barbara, Feracci, Mikael, Falcou, Camille, Gauffre, Pierre, El Kazzi, Priscila, Delpal, Adrien, Decroly, Etienne, Alvarez, Karine, Eydoux, Cécilia, Guillemot, Jean-Claude, Moussa, Adel, Good, Steven S., La Colla, Paolo, Lin, Kai, Sommadossi, Jean-Pierre, Zhu, Yingxiao, Yan, Xiaodong, Shi, Hui, Ferron, François, Canard, Bruno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8810794/
https://www.ncbi.nlm.nih.gov/pubmed/35110538
http://dx.doi.org/10.1038/s41467-022-28113-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8810794/
https://www.ncbi.nlm.nih.gov/pubmed/35110538
http://dx.doi.org/10.1038/s41467-022-28113-1

Ejemplares similares